PRESS RELEASE
News
-
-
PRESS RELEASE
VENCORA UK Limited publishes definitive notice of the interim result of the public tender offer for all publicly held registered shares in CREALOGIX Holding AG
VENCORA UK Limited has published the definitive notice of the interim result of its public tender offer for all publicly held registered shares in CREALOGIX Holding AG, showing that 96.24% of the issued share capital and voting rights have been tendered into the offer. Shareholders are advised of the additional acceptance period and the upcoming extraordinary shareholders' meeting. Visit the offer website for further details. -
PRESS RELEASE
VENCORA UK Limited publie l'annonce définitive du résultat intermédiaire de l’offre publique d’acquisition portant sur toutes les actions de CREALOGIX Holding AG en mains du public
VENCORA UK Limited publie l'annonce définitive du résultat intermédiaire de l’offre publique d’acquisition portant sur toutes les actions de CREALOGIX Holding AG en mains du public. L'annonce indique que VENCORA UK Limited détient 96.24% du capital-actions de CREALOGIX -
PRESS RELEASE
R&S Group announces preliminary 2023 topline results and increases FY 2024 guidance
R&S Group Holding AG announces the preliminary 2023 topline results, revealing a significant growth of 30% in net sales when excluding divested business. With an increased order backlog and positive business dynamics, the company has revised its FY 2024 guidance to a net sales growth of 9%-12% and an EBIT margin in the range of 16%-18%. The positive outlook is attributed to the encouraging momentum in the Group's end markets and the expected continuation of positive mega trends. For further details, the company will provide more information on 21 March 2024 with the publication of preliminary unaudited 2023 key figures. -
PRESS RELEASE
Mikron achieves marked increase in net sales with high order backlog
Mikron Holding AG has announced a significant increase in net sales and high order backlog for the 2023 financial year, with the Group exceeding the previous year's results. The strong demand in pharmaceutical and medical technology industries, coupled with good performance in all three divisions, contributed to this positive development. The Group expects further improvement in profitability compared to the previous year and will release detailed figures for 2023 on March 8, 2024. -
PRESS RELEASE
Rieter: First Information on the Financial Year 2023 Ad-hoc announcement pursuant to Art. 53 LR
Rieter Holding AG has released a preliminary update on the Financial Year 2023, as part of an ad-hoc announcement. The media and investor presentation is available in the attached media kit. -
PRESS RELEASE
Update - WPF Holdings Updates Prospects for 2024
WPF Holdings, Inc provides updates on its 2024 current projects and the status of several transactions initiated at the end of 2023, including the integration of the digital wallet, expansion of partnership with Woohoo, sales partnership for mobile devices and tablets, anticipated launch of live and streaming television services, and the acquisition of Virtual Health Holdings, Inc. The company also announces additional acquisitions agreements and emphasizes forward-looking statements in this regard. -
PRESS RELEASE
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages BioVie Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BIVI
The Rosen Law Firm, a trusted and leading law firm, is announcing a class action lawsuit on behalf of BioVie Inc. investors. The lawsuit alleges that BioVie made misleading statements about its business operations and COVID-19's impact on its clinical trial sites, resulting in damages to investors. If you purchased BioVie securities during the specified period, you may be entitled to compensation. Investors are encouraged to seek qualified counsel and can join the class action by contacting The Rosen Law Firm before the important deadline on March 19, 2024. -
PRESS RELEASE
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages AlloVir, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALVR
Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of AlloVir, Inc. If you purchased AlloVir securities during the Class Period, you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. Join the AlloVir class action by visiting the link provided or contacting the stated email and phone numbers for information. The lawsuit alleges that AlloVir made materially false and misleading statements regarding its business, operations, and prospects, leading to damages for investors. -
PRESS RELEASE
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Eagle Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - EGRX
The Rosen Law Firm, a global investor rights law firm, is encouraging Eagle Pharmaceuticals, Inc. investors to seek counsel before the important deadline in the securities class action. Investors who purchased Eagle Pharmaceuticals securities during the specified period may be entitled to compensation without payment of out-of-pocket fees through a contingency fee arrangement. The firm has a track record of success in leadership roles and represents investors in securities class actions and shareholder derivative litigation. For more information on the class action or to join, visit the provided website or contact the firm directly. The lawsuit claims that investors suffered damages, and no class has been certified yet.
